JG
EGRX

Jefferies Group’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Jefferies Group’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-3,100
Closed -$120K – 2506
2016
Q2 		$120K Buy
+3,100
New +$129K ﹤0.01% 1913
2016
Q1 		– Sell
-15,800
Closed -$1.4M – 2638
2015
Q4 		$1.4M Hold
15,800
– – 0.01% 1028
2015
Q3 		$1.17M Buy
+15,800
New +$1.31M 0.01% 1140

Other funds holding EGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Jefferies Group's EGRX Position: Q3 2016 in Review

Jefferies Group sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2016, closing a stake of 2,105 shares — an estimated $82K sold.

Jefferies Group first reported a position in EGRX in Q3 2015 and held it in 3 quarters. The position peaked at $533K in Q3 2015. 137 funds tracked by Wall St. Rank hold EGRX as of Q3 2016.

  • Jefferies Group reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2016 after selling out during the quarter.
  • Jefferies Group sold 2,105 Eagle Pharmaceuticals, Inc. shares in Q3 2016, an estimated $82K.
  • Jefferies Group first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2015 and held it in 3 quarters.
  • Jefferies Group's Eagle Pharmaceuticals, Inc. position peaked at $533K in Q3 2015.
  • 137 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2016.

Based on Jefferies Group's 13F filing for Q3 2016, filed 14 Nov 2016.